NKTR
Nektar Therapeutics
NASDAQ · Healthcare · Biotechnology · US
$74.19
−2.85%Margins
Gross margin
99.4%
EBITDA margin
-246.2%
EBIT margin
-240.4%
Net margin
-287.8%
FCF margin
-428.7%
-17.4%
Return on equity
-14.3%
Return on assets
-12.6%
Return on invested capital
0.06x
Asset turnover
-$233.8M
Cash from operations
$20
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026